Overview

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

Status:
Not yet recruiting
Trial end date:
2022-11-28
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, double-blind, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Subjects with Post-stroke Upper Limb Spasticity
Phase:
Phase 1
Details
Lead Sponsor:
CKD Bio Corporation